BDR Pharma Unveils Zisavel To Treat Invasive Aspergillosis & Mucormycosis

BDR Pharmaceutical, a major pharmaceutical business, has announced the introduction of Zisavel capsules, the first-of-its-kind generic medicine for the treatment of invasive aspergillosis and mucormycosis. Zisavel belongs to the isavuconazole class of drugs known as azole antifungals. Isavuconazole is an essential therapy for invasive aspergillosis. The product will be available as 100 mg capsules and is the first line of treatment for the aforementioned fungal infections.

The price of the generic drug will be Rs. 7,992/-, for 7 capsules which is 1/3rd the cost of present therapy available by Innovators. BDR Pharmaceutical aims to reduce the cost of therapy for invasive fungal diseases with isavuconazole to be on par with voriconazole and posaconazole (new-generation anti-fungal agents), making it more accessible to patients who are unable to afford it currently, as per pharmabiz.

According to data, the global prevalence of mucormycosis ranges from 0.005 to 1.7 per million persons. The prevalence of mucormycosis in India is reported to be 140 per million individuals, which is 70-80 times greater than in any other country. In India, the yearly incidence of invasive aspergillosis is estimated to be 2,50,900 cases, which include chronic obstructive pulmonary disease, lung cancer, leukaemia, lymphoma, or transplantation. Invasive aspergillosis cases will have caused roughly 2,360 fatalities by 2020.